Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human pancreatic islet transplantation is a cell therapy procedure developed by Ospedale San Raffaele for the treatment of type 1 diabetes mellitus. The procedure involves isolating insulin-producing islets of Langerhans from a donor pancreas and transplanting them into a recipient to restore endogenous insulin production and glycemic control. While the liver is the traditional site for transplantation (via the portal vein), Ospedale San Raffaele has specifically investigated the bone marrow as an alternative site. This approach aims to provide a more vascularized and protected environment for the transplanted cells, potentially improving islet engraftment and survival by avoiding the instant blood-mediated inflammatory reaction (IBMIR) typically encountered in the liver. The therapy is intended for patients with type 1 diabetes who experience severe hypoglycemic unawareness or metabolic instability despite intensive insulin therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Human pancreatic islet transplantation (Ospedale San Raffaele).